These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25603042)

  • 41. FDA medical device approval: things you didn't learn in medical school or residency.
    Buch B
    Am J Orthop (Belle Mead NJ); 2007 Aug; 36(8):407-12. PubMed ID: 17849025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The "natural" aversion: the FDA's reluctance to define a leading food-industry marketing claim, and the pressing need for a workable rule.
    Farris AL
    Food Drug Law J; 2010; 65(2):403-24, iv. PubMed ID: 24475548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. US FDA outreach to the regenerative medicine community: challenges and opportunities.
    Whittlesey KJ; Witten C
    Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Texas legitimizes path around FDA oversight.
    DeFrancesco L
    Nat Biotechnol; 2012 May; 30(5):379. PubMed ID: 22565948
    [No Abstract]   [Full Text] [Related]  

  • 46. Stem cell therapy: a challenge to periodontist.
    Mudda JA; Bajaj M
    Indian J Dent Res; 2011; 22(1):132-9. PubMed ID: 21525691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDA policy on unapproved drug products: past, present, and future.
    Chhabra R; Kremzner ME; Kiliany BJ
    Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current and Future Stem Cell Regulation: A Call to Action.
    Anz A
    Am J Orthop (Belle Mead NJ); 2016; 45(5):274-318. PubMed ID: 27552450
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stem cells. U.S. regulation of stem cells as medical products.
    Sipp D; Turner L
    Science; 2012 Dec; 338(6112):1296-7. PubMed ID: 23224541
    [No Abstract]   [Full Text] [Related]  

  • 50. Are stem cells drugs? The regulation of stem cell research and development.
    Rosen MR
    Circulation; 2006 Oct; 114(18):1992-2000. PubMed ID: 17075025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Letter campaign sought to pressure FDA action on stem cell clinics.
    Dolgin E
    Nat Med; 2014 Aug; 20(8):796-7. PubMed ID: 25100513
    [No Abstract]   [Full Text] [Related]  

  • 52. The FDA's role in medical device clinical studies of human subjects.
    Saviola J
    J Neural Eng; 2005 Mar; 2(1):S1-4. PubMed ID: 15876645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. European Medicines Agency, CAT Secretariat & US Food and Drug Administration.
    Regen Med; 2011 Nov; 6(6 Suppl):90-6. PubMed ID: 21999268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
    Weaver J; Grenade LL; Kwon H; Avigan M
    Dermatol Ther; 2009; 22(3):204-15. PubMed ID: 19453344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FDA's evolving approach to nanotechnology.
    Monica JC
    Food Drug Law J; 2012; 67(4):405-11, i. PubMed ID: 24640614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Revising the Regulation of Stem Cell-Based Therapies: Critical Assessment of Potential Models.
    von Tigerstrom B
    Food Drug Law J; 2015; 70(2):315-37, iii. PubMed ID: 26302602
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The new FDA combination products programme.
    Donawa M
    Med Device Technol; 2002 Oct; 13(8):25-8. PubMed ID: 12416330
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oversight for clinical uses of autologous adult stem cells: lessons from international regulations.
    Lysaght T; Kerridge I; Sipp D; Porter G; Capps BJ
    Cell Stem Cell; 2013 Dec; 13(6):647-51. PubMed ID: 24315438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stem cell science: current ethical and policy issues.
    Mauron A; Jaconi ME
    Clin Pharmacol Ther; 2007 Sep; 82(3):330-3. PubMed ID: 17637783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Science and regulation. FDA's approach to regulation of products of nanotechnology.
    Hamburg MA
    Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.